Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Stereotactic Radiotherapy of Meningiomas

Stereotactic Radiotherapy of Meningiomas Strahlentherapie und Onkologie Original Article Symptomatology, Acute and Late Toxicity 1 1 2 2 2 1 Martin Henzel , Markus W. Gross , Klaus Hamm , Gunnar Surber , Gabriele Kleinert , Thomas Failing , 1 1 Gerd Strassmann , Rita Engenhart-Cabillic Background and Purpose: Stereotactic radiosurgery (SRS) is well established in the treatment of skull base meningiomas, but this therapy approach is limited to small tumors only. The fractionated stereotactic radiotherapy (SRT) offers an alternative treat- ment option. This study aims at local control, symptomatology, and toxicity. Patients and Methods: Between 1997–2003, 224 patients were treated with SRT (n = 183), hypofractionated SRT (n = 30), and SRS (n = 11). 95/224 were treated with SRT/SRS alone. 129/224 patients underwent previous operations. Freedom from progres- sion and overall survival, toxicity, and symptomatology were evaluated systematically. Additionally, tumor volume (TV) shrinkage was analyzed three-dimensionally within the planning system. Results: The median follow-up was 36 months (range, 12–100 months). Overall survival and freedom from progression for 5 years were 92.9% and 96.9%. Quantitative TV reduction was 26.2% and 30.3% 12 and 18 months after SRT/SRS (p < 0.0001). 95.9% of the patients improved their symptoms or were stable. Clinically significant http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Strahlentherapie und Onkologie Springer Journals

Loading next page...
 
/lp/springer-journals/stereotactic-radiotherapy-of-meningiomas-pD0RepoHk3

References (40)

Publisher
Springer Journals
Copyright
Copyright © 2006 by Urban & Vogel München
Subject
Medicine & Public Health; Radiotherapy; Oncology
ISSN
0179-7158
eISSN
1439-099X
DOI
10.1007/s00066-006-1535-7
pmid
16826356
Publisher site
See Article on Publisher Site

Abstract

Strahlentherapie und Onkologie Original Article Symptomatology, Acute and Late Toxicity 1 1 2 2 2 1 Martin Henzel , Markus W. Gross , Klaus Hamm , Gunnar Surber , Gabriele Kleinert , Thomas Failing , 1 1 Gerd Strassmann , Rita Engenhart-Cabillic Background and Purpose: Stereotactic radiosurgery (SRS) is well established in the treatment of skull base meningiomas, but this therapy approach is limited to small tumors only. The fractionated stereotactic radiotherapy (SRT) offers an alternative treat- ment option. This study aims at local control, symptomatology, and toxicity. Patients and Methods: Between 1997–2003, 224 patients were treated with SRT (n = 183), hypofractionated SRT (n = 30), and SRS (n = 11). 95/224 were treated with SRT/SRS alone. 129/224 patients underwent previous operations. Freedom from progres- sion and overall survival, toxicity, and symptomatology were evaluated systematically. Additionally, tumor volume (TV) shrinkage was analyzed three-dimensionally within the planning system. Results: The median follow-up was 36 months (range, 12–100 months). Overall survival and freedom from progression for 5 years were 92.9% and 96.9%. Quantitative TV reduction was 26.2% and 30.3% 12 and 18 months after SRT/SRS (p < 0.0001). 95.9% of the patients improved their symptoms or were stable. Clinically significant

Journal

Strahlentherapie und OnkologieSpringer Journals

Published: Jan 1, 2006

There are no references for this article.